Modern Australian
Men's Weekly

.

We may have to accept a 'good enough' COVID-19 vaccine, at least in 2021

  • Written by Paul Komesaroff, Professor of Medicine, Monash University

Australian health minister Greg Hunt said recently the government is on track to deliver COVID-19 vaccines from March 2021.

US biotech firm Moderna has just announced its COVID-19 vaccine has 95% efficacy, following on the heels of Pfizer’s claimed 90% efficacy and the Russian Sputnik V vaccine’s 92% efficacy, albeit based on limited data and yet to be peer-reviewed.

We’ll likely see more preliminary results from other vaccine trials reported in the media in coming weeks and months.

While an effective vaccine will provide the best chance of controlling the disease, it is sadly not so simple. No vaccine will be perfect or end the pandemic instantly. The first vaccines are also likely to have significant limitations.

The issue is how good a vaccine is good enough? We also need to think about what imperfections we — as individuals, regulators or governments — will be prepared to accept.

How safe is safe enough?

Safety is obviously the major concern. Vaccines are designed to be given to very large numbers of healthy people. This means even an extremely rare, serious adverse event, when applied to a population of millions, can produce major harm.

Short-term trials on small population samples relative to the numbers expected to receive the vaccine may also not be able to pick up relatively rare but important risks. This is a problem we may not be able to avoid because the only way to find out is to give the vaccine to large numbers of people and then allow long periods of time to elapse, for any long-term adverse events to become evident.

Obviously, all therapeutic agents carry the possibility of adverse effects and in individual cases decisions have to be made about whether the potential benefits justify taking the risks. It is arguable that the extreme dangers associated with COVID-19 justify accepting a higher level of risk for the vaccine. However, while the US and Australian regulatory authorities have broad guidelines relating to vaccine safety, neither has issued guidelines regarding the levels of risk that are considered justified for a coronavirus vaccine, and there has been only limited public debate on this subject.

Read more: Who pays compensation if a COVID-19 vaccine has rare side-effects? Here's the little we know about Australia's new deal

How effective is good enough?

Efficacy — the vaccine’s ability to produce clinical and public health benefits — is also uncertain.

Ideally, a vaccine should prevent any person who receives it from catching the disease. However, at least with the first vaccines, it is likely the benefits will be more limited. For example, they may slightly reduce the severity of the illness, or they may only benefit a small subset of the population. No current trials are looking at purely whether the vaccine will reduce the chance of dying from COVID-19 of individuals in specific risk groups.

In fact, different clinical trials have different “efficacy end points”, including (among others) effects on susceptibility to infection, severity of disease, time to recovery and mortality, in different age and population groups.

Elderly people in a nursing home doing group exercise sitting down There is no guarantee vaccines will provide significant protection for those in most need, such as people in older age groups. Shutterstock

There is no guarantee vaccines under development will provide significant protection for those in most need, such as people in older age groups or those with existing medical conditions. Not all trials are specifically recruiting such participants and there is a real possibility benefits will not extend to them. In other words, a clinical trial might show “efficacy” in a formal sense but might not solve the key problems we are facing in the real world.

Read more: Pfizer vaccine: what an 'efficacy rate above 90%' really means

Earlier this year, the US Food and Drug Administration said it would only consider approving vaccines that “prevent disease or decrease its severity in at least 50% of people who are vaccinated”. Australia’s equivalent, the Therapeutic Goods Administration, has not issued any similarly precise guidance.

How equitable is good enough?

Access and distribution of any vaccine pose major problems. Some of these are built into the nature of the product itself.

For example, vaccines like the mRNA vaccine developed by Pfizer that need to be transported and stored at around -70℃, will have limited utility in low and middle income countries with limited health infrastructure and in rural and remote communities all over the world – meaning other vaccines may need to be found for these populations.

Read more: Keeping coronavirus vaccines at subzero temperatures during distribution will be hard, but likely key to ending pandemic

The role of minorities in relation to clinical studies of therapeutic products in the US is very uneven, in terms of participation, exposure to risk and access to benefits. There is a serious chance that in the search for a COVID-19 vaccine those least likely ultimately to receive the final product will be the ones who carry the greatest risk. This creates a possibility the social divisions already exposed by the COVID crisis will be further exacerbated.

Further, while there has been widespread acknowledgement of the need for access and supply of COVID vaccines to poorer nations there is no legal structure to ensure this and no guarantee it will actually happen.

Read more: Australia's just signed up for a shot at 9 COVID-19 vaccines. Here's what to expect

Where to next?

A number of COVID-19 vaccines will likely become available during 2021 that offer either limited protection from infection or lower the risk somewhat of severe disease. However, these benefits may not necessarily be for those most at risk.

Robust regulatory systems, and independent scrutiny of clinical trial results, mean COVID-19 vaccines will likely be safe in the short-term. However, no-one will know about long-term risks and distribution may be limited, for logistic, economic and cultural reasons.

Even if we develop a “good enough” vaccine, there are no guarantees. Although many will be prepared to chance the first vaccines, many others will refuse them, despite government attempts at persuasion.

So herd immunity via vaccination, which for the coronavirus requires effective immunisation of at least two-thirds of the population, will remain a long way away.

This means strategies to reduce the spread, such as physical distancing, use of face masks and hand hygiene and, where necessary, rigorous quarantine measures, will be with us for some time.

Authors: Paul Komesaroff, Professor of Medicine, Monash University

Read more https://theconversation.com/we-may-have-to-accept-a-good-enough-covid-19-vaccine-at-least-in-2021-148168

Powering Shepparton’s Businesses: Expert Commercial Electrical Services You Can Count On

When it comes to running a successful business, having reliable, compliant, and efficient electrical systems is non-negotiable. From small retail ou...

Maximise Efficiency: Cleaner Solar Panels for Optimal Performance

Solar panels are a smart investment in energy efficiency, sustainability, and long-term savings—especially here in Cairns, where the tropical sun ...

7 Common Air Conditioner Issues in Melbourne – And How to Fix Them

Image by freepik Living in Melbourne, we all know how unpredictable the weather can be. One moment it’s cold and windy, the next it’s a scorchin...

Powering Palm QLD with Reliable Electrical Solutions

Image by pvproductions on Freepik When it comes to finding a trustworthy electrician Palm QLD locals can count on, the team at East Coast Sparkies s...

The Smart Way to Grow Online: SEO Management Sydney Businesses Can Rely On

If you’re a Sydney-based business owner, you already know the digital space is crowded. But with the right strategy, you don’t need to shout the...

What Your Car Says About You: The Personality Behind the Vehicle

You can tell a lot about someone by the car they drive—or at least, that’s what people think. True Blue Mobile Mechanics reckon the car says a l...

The Confidence Curve: Why Boudoir Photography Is the Empowerment Trend You Didn’t Know You Needed

Boudoir photography has been quietly taking over social feeds, Pinterest boards, and personal milestones—and for good reason. It’s not just abou...

Understanding Level 2 Electricians: Why Sydney Residents Need Licenced Experts for Complex Electrical Work

When it comes to electrical work around the home or business, not all electricians are created equal. In Sydney, particularly when you're dealing wi...

Retirement Anchored in Model Boat Building for Waterford’s Doug Unsold

WATERFORD — When Doug Unsold sees his ship come in, it’s usually one he’s crafted with his own hands. The 67-year-old retiree from Waterford ...

The Science Behind Alarm Clocks and Your Circadian Rhythm

Waking up on time isn’t just about setting an alarm—it’s about working with your body, not against it. At the heart of every restful night and...

How to Use Plants to Create a Calming Atmosphere in Your Home

In today’s fast-paced world, cultivating a calm, soothing environment at home has never been more important. Whether you live in a busy urban apar...

How Maths Tutoring Can Help Students Master Maths

Mathematics can be a daunting subject for many students, often causing stress and frustration. However, maths tutoring has proven to be an effective...

Refurbished iPads Are Better Than New Ones (Here's Why)

Image by rawpixel.com on Freepik Apple's refurbished iPad program has quietly become one of the best deals in tech. While everyone obsesses over the ...

Your Guide to Finding the Right GP: What Perth City Doctors Offer Today

Choosing a General Practitioner (GP) is one of the most important health decisions you’ll make. Luckily, Perth’s vibrant CBD now hosts a new ge...

Why Every Mining Operation Needs a Robust Safety Management System

Mining is one of the backbones of the Australian economy, particularly in Western Australia. Back in 2019-20, mining contributed 10.4% of Australia...

Australian Classic Literature Enjoys Resurgence

Welcome back to the good old days of storytelling! As the modern world becomes increasingly more demanding, returning to childhood favourites offers...

How to Choose the Right Lawyers in Sydney for Your Situation

When faced with a legal issue, selecting the right legal representation can make all the difference. Whether you're dealing with a personal injury, ...

Building a Governance Model for Headless Content Management at Scale

Image by pch.vector on Freepik There's never been a better time to implement a headless content management system (CMS) to gain the flexibility and ...